Floatz logo

Prior Mb-106 Car-T Cell Investigational Product.

CD4+/CD56+ Hematodermic Neoplasm

Mustang BioCell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the CD4+/CD56+ Hematodermic Neoplasm cohort.

Asset / SponsorPhaseRating
Tagraxofusp
French Innovative Leukemia Organisation
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB
DEXAMETHASONE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B

View all 47 →

Same molecule, other indications

Prior Mb-106 Car-T Cell Investigational Product. is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
D
Indicative ·
30 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
D
Indicative ·
30 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →